Triggers for driving treatment of at-risk patients with invasive fungal disease

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue SUPPL3, 2013, Pages

  Drgona, Luboš ^a   Colita, Anca ^b   Klimko, Nikolay ^c   Rahav, Galia ^d   Ozcan, Mehmet A ^e   Donnelly, J Peter ^f  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

^c NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^d SHEBA MEDICAL CENTER   (Israel)

^e DOKUZ EYLUL UNIVERSITY   (Turkey)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnostic driven therapy; Galactomannan test; Immunocompromised patients; Radiological triggers

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BIOLOGICAL MARKER; CASPOFUNGIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS; BRONCHOSCOPY; CROSS REACTION; CRYPTOCOCCUS NEOFORMANS; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HISTOPLASMA CAPSULATUM; HUMAN; LUNG LAVAGE; PENICILLIUM MARNEFFEI; RISK FACTOR; SYSTEMIC MYCOSIS; TRICHOSPORON;

DIAGNOSTIC-DRIVEN THERAPY; GALACTOMANNAN TEST; IMMUNOCOMPROMISED PATIENTS; RADIOLOGICAL TRIGGERS;

ANTIFUNGAL AGENTS; DIAGNOSTIC TESTS, ROUTINE; FEVER OF UNKNOWN ORIGIN; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84886638926     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt391     Document Type: Article

References (55)

1. Worth LJ, Slavin MA. Bloodstream infections in haematology: risks and new challenges for prevention. Blood Rev 2009; 23: 113-22.
2. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
3. Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? Brit J Haematol 2011; 153: 681-97.
4. Zaragoza R, Peman J, Salavert M et al. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? Ther Clin Risk Manag 2008; 4: 1261-80.
5. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J InfectDis 1995; 171: 1545-52.
6. Cornely OA, Maertens JA, Drew J et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
7. Maertens J, Theunissen K,Verhoef Get al. Galactomannanand computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
8. Girmenia C, Micozzi A, Gentile G et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010; 28: 667-74.
9. Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomised, controlled trial. Clin Infect Dis 2009; 48: 1042-51.
10. Barnes RA, White PL, Bygrave C et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high risk haematology and stem cell transplant patients. J Clin Pathol 2009; 62: 64-9.
11. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
12. Calliot D, Mannone L, Cuisenier B et al. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect 2001; 7: 54-61.
13. Maaroufli Y, DeBruyne JM, Duchteau V et al. Early detection and identification of commonly encountered Candida species from simulated blood cultures by using a real-time PCR-based assay. J Mol Diagn 2004; 6: 108-14.
14. Morrissey CO, Chen SC, Sorrell TC et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet infect Dis 2013; 13: 519-28.
15. White PL, Bretagne S, Klingspor Let al. Aspergillus PCR; one step closer to standardization. J Clin Microbiol 2010; 48: 1213-40.
16. Maertens JA, Nucci M, Donnelly JP et al. The role of antifungal treatment in hematology. Haematologica 2012; 97: 325-7.
17. Akan H, Antia VP, Kouba M et al. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects. J Antimicrob Chemother 2013; 68 Suppl 3: iii5-15.
18. Von Eiff M, Roos N, Schullten R et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62: 341-7.
19. Pizzo PA, Robichaud KJ, Gill FA et al. Empirical antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-11.
20. EORTC International Antimicrobial Therapy Cooperative Group. Empirical antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668-72.
21. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
22. Maertens J,Marchetti O, Herbrecht Ret al. Third European Conferenceon Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011; 46: 709-6.
23. Winston DJ, Hathorn JW, Schuster MG et al. A multicenter, randomised trial of fluconazole versus amphotericin B for empirical antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108: 282-9.
24. Boogaerts M,Winston DJ,Bow EJ et al. Intravenousandoral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad spectrum antibacterial therapy. A randomized controlled trial. Ann InternMed 2001; 135: 412-22.
25. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-71.
26. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
27. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
28. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropenic cancer patients with persistent fever. Eur J Cancer Suppl 2007; 5: 32-42.
29. Madureira A, Berganon A, Larcoix C et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007; 30: 551-4.
30. Turner SJ, Chen SC, Slavin MA et al. Pharmacoeconomics of empirical antifungal use in febrile neutropenic haematological malignancy and haematopoietic stem cell transplant. Expert Rev Pharmacoecon Outcomes Res 2013; 13: 227-35.
31. Amanda-Rajah MR, Morrissey CO, Spelman T et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk haematology patients: an economic modelling approach. Antimicrob Agents Chemother 2011; 55: 1953-60.
32. Maertens J, Groll AH,Cordonnier C et al. Treatmentandtiming of invasive mould disease. J Antimicrob Chemother 2011; 66 Suppl 1: i37-43.
33. Dignan FL, Evans SO, Ethell ME et al. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant 2009; 44: 51-6.
34. Aguilar-Guisado M, Martín-Peña A, Espigado I et al. Universal antifungal therapy is not needed in persistent febrile neutropenia: atailored diagnostic and therapeutic approach. Haematologica 2012; 97: 464-71.
35. Schwarzinger M, Saganon-Teyssier L, Cabaret O et al. Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: amulti-statemodel. PLoS One 2013; 8: e65776.
36. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-57.
37. Wheat LJ. Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin Chest Med 2009; 30: 367-77.
38. TM) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother 2012; 67: 1746-8.
39. Cummings JR, Jamison GR, Boudreaux JW et al. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis 2007; 59: 113-5.
40. Martín-Rabadán P, Gijón P, Fernández RA et al. False-positive Aspergillus antigenemia due to blood product conditioning fluids. Clin Infect Dis 2012; 55: e22-7.
41. Hashiguchi K, Niki Y, Soejima R. Cyclophosphamide induces falsepositive results in detection of Aspergillus antigen in urine. Chest 1994; 105: 975.
42. Georgiadou SP, Sipsas NV, Marom EM et al. The diagnostic value of halo and reverse halo signs for invasive mould infections in compromised host. Clin Infect Dis 2011; 52: 1144-55.
43. Arendrup MC, Bille J, Dannaoui E et al. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant 2012; 47: 1030-45.
44. Marchetti O, Lamoth F, Mikukska Met al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47: 846-54.
45. Marková M, Brodská H, Malíčková K et al. Substantially elevated C-reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients. Support Care Cancer 2013; 21: 2733-42.
46. Villarroel M, Avilés CL, Silva P et al. Risk factors associated with invasive fungal disease in childrenwith cancerandfebrile neutropenia:aprospective multicenter evaluation. Pediatr Infect Dis J 2010; 29: 816-21.
47. Kikuchi M, Nakasone H, Mitani K et al. Retrospective assessment of secondary prophylaxis for invasive aspergillosis in neutropenic hematology patients and identification of risk factors for relapse of fungal disease. Scand J Infect Dis 2013; 45: 531-6.
48. Artz AS, Wickrema A, Dinner S et al. Pre-treatment C-reactive protein (CRP) is a predictor for allogeneic hematopoietic cell transplantation outcomes. Biol Blood Marrow Transplant 2008; 14: 1209-16.
49. Blijlevens NM, Donnelly JP, DePauw BE. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2005; 36: 703-7.
50. Koya J, Nannya Y, Ichikawa M et al. The clinical role of procalcitonin in hematopoietic SCT. Bone Marrow Transplant 2012; 47: 1326-31.
51. Pagano L, Fianchi L, Leone G. Fungal pneumonia due to molds in patients with hematological malignancies. J Chemother 2006; 18: 339-52.
52. Hori A, Kami M, Kishi Y et al. Clinical significance of extra-pulmonary involvement of invasive aspergillosis: a retrospective autopsy-based study of 107 patients. J Hosp Infect 2002; 50: 175-82.
53. Avni T, Levy I, Sprecher H et al. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. J Clin Microbiol 2012; 50: 3652-8.
54. Barnes A. Directed therapy for fungal infections: focus on aspergillosis. J Antimicrob Chemother 2013; 68: 2431-2434.
55. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 14: 580-637.